Valneva shares slump after the companies said the study's primary endpoint didn't meet statistical significance Pfizer and Valneva plan to seek regulatory approval for a Lyme disease vaccine.

Add Yahoo as a preferred source to see more of our stories on Google. The Pfizer company logo is displayed as traders work on the floor of the New York Stock Exchange during morning trading on April ...

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions Pfizer to leverage Chi ...

Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...